Center news & funding
VCU Massey Cancer Center researcher John Hackett, Ph.D., is at the forefront of integrating computer simulations with laboratory experiments to understand complex biological systems at the molecular level. His work has tremendous implications for the development of drugs to treat a range of diseases and is so significant that the National Institutes of Health has funded his team for more than a decade. Earlier this year, Hackett received a four-year, $1.5 million R01 grant from the National Institute of General Medical Sciences (NIGMS) to unlock the secrets of cytochromes P450 (CYPs).
VCU Massey Cancer Center researcher Larisa Litovchick, M.D., Ph.D., was recently awarded $465,000 from the National Institute of Dental and Cranial Research to further investigate how human papillomavirus (HPV) leads to head and neck cancers. Findings may aid the development of novel targeted treatments.
$2.3 million grant from the National Cancer Institute funds new viral-based gene therapies for lung cancer at Massey
Mutations in the p53 gene are found in more than half of all cancers, yet it has proven to be very difficult to target the gene with therapeutic drugs even 40 years after its discovery. VCU Massey Cancer Center researchers Sumitra Deb, Ph.D., and Brad Windle, Ph.D., are hoping to turn the tide with an innovative viral-based strategy, and they recently received more than $2 million from the National Cancer Institute to fund their work.
VCU Massey Cancer Center researcher Dipankar Bandyopadhyay, Ph.D., was recently elected as a member of the prestigious International Statistical Institute.
The International Statistical Institute (ISI) is a nonprofit organization founded in 1885 to promote the understanding, development and good practice of statistics worldwide. Elected membership is open to individuals who are established in their careers and have made noteworthy contributions to the statistical profession.
VCU Massey Cancer Center researchers have been awarded a grant totaling more than $1.4 million over four years from the National Cancer Institute (NCI) to drive the development of a new treatment for MYCN-amplified neuroblastoma, an aggressive subset of pediatric nervous system cancer marked by overexpression of the MYCN gene. There are limited treatments currently available for MYCN-amplified neuroblastoma, and it is among the deadliest of the pediatric cancers.